OptiRTP to Represent New Zealand at the 2026 SelectUSA Investment Summit
The SelectUSA Investment Summit at the Gaylord National Resort & Convention Center, National Harbor, Maryland. Photo: SelectUSA / U.S. Department of Commerce.
OptiRTP has been selected by the U.S. Commercial Service to join the New Zealand delegation to the 2026 SelectUSA Investment Summit, taking place May 3-6 at the Gaylord National Resort & Convention Center in National Harbor, Maryland.
The SelectUSA Investment Summit is the highest-profile event in the United States dedicated to foreign direct investment, hosted by the International Trade Administration within the U.S. Department of Commerce. The U.S. Commercial Service - operating through the American Embassy in Wellington - evaluated and accepted OptiRTP into the official 2026 Australia-New Zealand Delegate Directory. The Summit brings together economic development organisations from all 54 U.S. states and territories, federal agency representatives, investors, and service providers for a week of bilateral meetings and presentations.
OptiRTP's selection follows a series of U.S. market engagement milestones. The company has been featured by the American Chamber of Commerce New Zealand as "Invest in NZ MedTech Going Global." CEO Jon Doherty and Founder Bogdan Anich presented OBST to a Utah state delegation led by Governor Spencer J. Cox at an AmCham briefing during Auckland Start-Up Week. OptiRTP is pursuing permanent U.S. commercial operations, including American manufacturing partnerships and a planned 180-patient VA clinical trial for its FDA-registered Class I medical device, OBST (Optimum Bio Sound Therapy).
OptiRTP will also take part in the Washington, DC: Your Global Gateway to Innovation spinoff on May 7, reflecting the relevance of acoustic neuromodulation technology across both health and military force readiness applications.
Event details: 2026 SelectUSA Investment Summit
About OptiRTP
OptiRTP (Return to Play) is a New Zealand-based biotech company. Its core technology, OBST (Optimum Bio Sound Therapy), has 352,000+ documented therapy hours with zero serious adverse events reported. OBST is an FDA-registered Class I medical device, 510(k)-exempt (registration and listing, not FDA clearance or approval), that uses dynamic, patterned acoustic neuromodulation via the auditory pathway, with a proposed mechanism involving modulation of central autonomic regulatory networks associated with sleep, pain, recovery and stress regulation. Drug-free and non-invasive, used passively during sleep or rest through a tablet and earbuds. Users can follow recovery markers on their own wearable.
